Preclinical progress in the target validation of viroporins: candidates for potential target therapy

INTRODUCTION: Numerous viral infections necessitate immediate attention, underscoring the urgent need for effective antiviral drugs that can directly inhibit viral functions or indirectly manipulate host factors. Most direct-acting antiviral drugs target two specific viral components: polymerases (including reverse transcriptases) and proteases. Focusing on this narrow range of targets limits the scope of drug development and favors rapid resistance emergence. Therefore, targeting alternative viral components, such as viroporins, is advantageous. Viroporins constitute a family of small hydrophobic proteins encoded by viruses that oligomerize to form ion channels, thereby playing crucial roles in various stages of the viral infectivity cycle. Despite their functional significance, they have received considerably less attention from the pharmaceutical industry compared to traditional viral targets. AREA COVERED: This review delves into the significance of viral channels as potential therapeutic targets, surveying recent advancements and the prospects for future breakthroughs. Viroporins from diverse viral families and their potential inhibition by small molecules are discussed, with special emphasis on bacteria-based channel assays that facilitate high-throughput screening of channel blockers. EXPERT OPINION: Bacteria-based assays enable rapid discovery and preemptive resistance mapping, while conserved pore architectures raise the prospect of broadspectrum inhibitors. However, clinical translation requires addressing selectivity, toxicity, and pharmacokinetic challenges.

Authors

Institutions

Publication Details

Journal
Expert Opinion on Therapeutic Targets
Published
2026-11-20
DOI
https://doi.org/10.1080/14728222.2026.2761688
Primary Topic
Ion channel regulation and function
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Preclinical progress in the target validation of viroporins: candidates for potential target therapy

Kingshuk Basu, Isaiah Tuvia Arkin
1 links
Expert Opinion on Therapeutic Targets
Ion channel regulation and function
article

Preclinical progress in the target validation of viroporins: candidates for potential target therapy

Kingshuk Basu, Isaiah Tuvia Arkin
article en

Abstract

INTRODUCTION: Numerous viral infections necessitate immediate attention, underscoring the urgent need for effective antiviral drugs that can directly inhibit viral functions or indirectly manipulate host factors. Most direct-acting antiviral drugs target two specific viral components: polymerases (including reverse transcriptases) and proteases. Focusing on this narrow range of targets limits the scope of drug development and favors rapid resistance emergence. Therefore, targeting alternative viral components, such as viroporins, is advantageous. Viroporins constitute a family of small hydrophobic proteins encoded by viruses that oligomerize to form ion channels, thereby playing crucial roles in various stages of the viral infectivity cycle. Despite their functional significance, they have received considerably less attention from the pharmaceutical industry compared to traditional viral targets. AREA COVERED: This review delves into the significance of viral channels as potential therapeutic targets, surveying recent advancements and the prospects for future breakthroughs. Viroporins from diverse viral families and their potential inhibition by small molecules are discussed, with special emphasis on bacteria-based channel assays that facilitate high-throughput screening of channel blockers. EXPERT OPINION: Bacteria-based assays enable rapid discovery and preemptive resistance mapping, while conserved pore architectures raise the prospect of broadspectrum inhibitors. However, clinical translation requires addressing selectivity, toxicity, and pharmacokinetic challenges.

Expert Opinion on Therapeutic Targets
City University of Hong Kong (HK), Hebrew University of Jerusalem (IL)
United States - Israel Binational Agricultural Research and Development Fund, City University of Hong Kong, Israel Science Foundation, National Institutes of Health
Good health and well-being
Ion channel regulation and function
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon